A paradigm for Africa-centric vaccine development in Equatorial Guinea

Peter F Billingsley; Thomas L Richie; Salim Abdulla; Mitoha Ondo'o Ayekaba; Claudia A Daubenberger; Guíllermo A Garcia; Stephen L Hoffman

doi:10.1016/j.pt.2024.03.005

A paradigm for Africa-centric vaccine development in Equatorial Guinea

Trends Parasitol. 2024 May;40(5):362-366. doi: 10.1016/j.pt.2024.03.005. Epub 2024 Apr 5.

Authors

Peter F Billingsley¹, Thomas L Richie², Salim Abdulla³, Mitoha Ondo'o Ayekaba⁴, Claudia A Daubenberger⁵, Guíllermo A Garcia⁶, Stephen L Hoffman²

Affiliations

¹ Sanaria Inc., 9800 Medical Center Drive, Rockville, MD 20850, USA. Electronic address: pbillingsley@sanaria.com.
² Sanaria Inc., 9800 Medical Center Drive, Rockville, MD 20850, USA.
³ Bagamoyo Research and Training Center, Ifakara Health Institute, Bagamoyo, Tanzania.
⁴ Ministry of Health and Social Welfare, Government of the Republic of Equatorial Guinea, Malabo, Bioko Norte, Equatorial Guinea.
⁵ Swiss Tropical and Public Health Institute, Kreuzstrasse 2, 4123 Allschwil, Switzerland; University of Basel, Peterplatz 1, 4001 Basel, Switzerland.
⁶ MCD Global Health, 8403 Colesville Rd, Suite 320, Silver Spring, MD 20910, USA.

PMID: 38582683
DOI: 10.1016/j.pt.2024.03.005

Abstract

The Equatorial Guinea Malaria Vaccine Initiative (EGMVI) highlights how long-term African government and international energy industry investment, plus novel partnerships, can enable clinical development of vaccines in Africa, for Africa. We review achievements and challenges of this pioneering, award-winning, public-private partnership which offers a model for future Africa-centric clinical research and development (R&D).

Keywords: PfSPZ vaccine; Plasmodium falciparum; elimination; malaria.

Publication types

Review
Research Support, Non-U.S. Gov't

MeSH terms

Africa
Equatorial Guinea
Humans
Malaria / prevention & control
Malaria Vaccines* / immunology
Public-Private Sector Partnerships
Vaccine Development*

Substances

Malaria Vaccines